Vertex nearing goal on hepatitis C drug
Cambridge firm locked in battle with Merck & Co.
After years of developing what it hopes will be a blockbuster drug to treat the hepatitis C virus, Vertex Pharmaceuticals Inc. of Cambridge is rapidly closing in on its goal: a product that could generate billions of dollars in annual revenue. (Full article: 761 words)
This article is available in our archives:
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass